Atyr PHARMA (NASDAQ:ATYR – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $35.00 price objective on the stock.
Atyr PHARMA Stock Performance
Atyr PHARMA stock opened at $1.98 on Thursday. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.02. Atyr PHARMA has a 12-month low of $1.08 and a 12-month high of $2.50. The stock has a market cap of $136.64 million, a P/E ratio of -2.20 and a beta of 1.25.
Insider Buying and Selling
In related news, Director Paul Schimmel acquired 52,300 shares of Atyr PHARMA stock in a transaction that occurred on Wednesday, July 24th. The shares were purchased at an average cost of $1.93 per share, for a total transaction of $100,939.00. Following the acquisition, the director now owns 413,023 shares in the company, valued at $797,134.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 3.70% of the stock is currently owned by company insiders.
Atyr PHARMA Company Profile
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company’s lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
See Also
- Five stocks we like better than Atyr PHARMA
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Procter & Gamble Stock Drops Despite Earnings Beat – What to Know
- How to Invest in the Best Canadian Stocks
- Financial Sector Shines as Key Players Continue to Beat Earnings
- How to Evaluate a Stock Before Buying
- Russell 2000 Index Bull Run: This ETF is Poised for Growth
Receive News & Ratings for Atyr PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.